A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

This is a randomized, placebo-controlled Phase 2 study in moderate to severe HS, which is the right design for signal detection, but the setup still looks more miss-prone than hit-prone. The endpoint is HiSCR75 at Week 16, a clinically meaningful and fairly stringent bar; requiring a 75% lesion reduction is tougher than lower-threshold response metrics and leaves less room for borderline efficacy. HS is also a noisy inflammatory disease with heterogeneous baseline burden, variable flare patterns, and nontrivial placebo response, all of which can dilute treatment separation. Two active regimens help by giving the program two dose/exposure shots on goal, but they also imply dose optimization is not yet settled, which is typical Phase 2 risk. The study is in a refractory moderate-to-severe population, further raising execution difficulty. Primary completion has passed while the status remains Active Not Recruiting, adding some operational and disclosure risk. Overall, I see modestly below-even odds of a positive readout.

AVTX-009 targets IL-1β selectively in a Phase 2 HS trial with ~250 patients and HiSCR75 at Week 16 as the primary endpoint. The IL-1β pathway has partial validation: AbbVie's lutikizumab (dual IL-1α/β) achieved HiSCR75 in up to 45.9% vs 17.5% placebo in a Phase 2 anti-TNF failure population, and Novartis' MAS825 showed benefit. However, AVTX-009 targets only IL-1β—bermekimab (IL-1α alone) and MEDI9868 (IL-1R) both failed in HS, suggesting pathway nuance matters. AVTX-009 has no prior HS efficacy data; this is its first controlled test. HiSCR75 is a stringent endpoint. Phase 2 historical success rates in dermatology/immunology are roughly 30-40%. The pathway signal from lutikizumab lifts the probability above base rate, but the selectivity risk, high endpoint bar, lack of prior clinical signal, and small-company execution risk cap it below 50%. Primary completion passed in Feb 2026; topline expected Q2 2026 but no data disclosed yet, consistent with normal analysis timelines. Well-funded with $98M cash.

This is a Phase 2 trial for AVTX-009 in moderate to severe hidradenitis suppurativa (HS). The primary endpoint is HiSCR75 at Week 16, which is a validated and clinically meaningful response measure. The trial is past its primary completion date by 38 days, suggesting data may be imminent. Without explicit prior data on AVTX-009's mechanism or Phase 1 results, and given the inherent uncertainty of Phase 2 proof-of-concept trials, the intrinsic probability sits near even odds. HS is a challenging indication with variable placebo response rates, and while IL-17/IL-23 inhibitors have shown efficacy in similar indications, AVTX-009's specific profile is unknown. The balanced risk-reward profile supports a 50% base case with low confidence.

This Phase 2 trial in hidradenitis suppurativa (HS) faces significant uncertainty. The primary endpoint, HiSCR75 at Week 16, is a high bar. Prior data for AVTX-009 is not disclosed, creating a blind spot. The sponsor, Avalo Therapeutics, is a micro-cap biotech with limited resources, increasing operational and disclosure risks. While the trial is completed (days to primary completion: -38), no topline results have been announced, suggesting a potential delay or negative outcome. The design is standard (placebo-controlled), but without prior efficacy signals in HS, the intrinsic probability is low.

Trial design is placebo-controlled with two AVTX-009 regimens, standard for Phase 2 dose-finding. Primary endpoint HiSCR75 at Week 16 demands ≥75% reduction in abscesses/inflammatory nodules with no increase in abscesses/fistulas—validated, clinically meaningful, but stringent vs common HiSCR50 (e.g., adalimumab HiSCR50 46% vs 18% placebo; HiSCR75 deltas ~15-20% in secukinumab/bimekizumab trials). Moderate-severe HS population standard and label-aligned. No enrollment specified (Ph2 norms ~150-300 total, adequate power feasible for moderate effect). No prior data in summary; novel AVTX-009 from small biotech AVTX raises mechanism/execution risk vs proven IL-17/TNF inhibitors. Operational: primary completion 38 days past, 'Active Not Recruiting' suggests low dropout/interim risk, imminent topline. Disclosure risk moderate—small sponsor may highlight signals but binary readout. Phase 2 immunology HS success ~45%, derated for endpoint rigor/lack priors: 42% YES.

AVTX-009 is an anti-IL-1β antibody targeting IL-1β, which has shown promise in hidradenitis suppurativa (HS) due to the role of IL-1β in the inflammatory cascade. The phase 2 trial design is well-structured, and while IL-17 inhibitors have shown efficacy in HS, the IL-1β pathway is a rational and promising target. The primary endpoint, HiSCR75, is a validated endpoint, and the mechanism is sound. However, HS trials often face high placebo response rates, and while IL-1β inhibition is scientifically sound, it is not yet clinically proven. The trial's completion status suggests data is being processed, and given the strong mechanistic rationale and the unmet need in HS, a positive outcome is slightly more probable than not.

Phase 2 HS trials with IL-17A inhibitors have historically shown mixed results. AVTX-009 is an anti-IL-17A monoclonal antibody, a validated mechanism in HS (secukinumab approved, ixekizumab failed Phase 3). The primary endpoint HiSCR75 at Week 16 is clinically meaningful and aligns with regulatory standards. Two active regimens suggest dose-finding flexibility. The trial completed enrollment with primary completion 38 days ago, indicating data lock imminent. No public top-line results yet creates information asymmetry risk. Historical placebo response in HS ranges 20-30%, and active arms typically achieve 45-55% HiSCR75 for effective IL-17 inhibitors. The 2:2:1 randomization provides reasonable power. Sponsor AVTX is micro-cap with high disclosure volatility. Overall, modest positive bias given mechanism validation and standard endpoint, tempered by competitive failures and small company execution risk.

The LOTUS Phase 2 trial of AVTX-009 in moderate-to-severe Hidradenitis Suppurativa (HS) carries significant clinical risk. AVTX-009 is an anti-IL-1β monoclonal antibody. While the IL-1 pathway is implicated in HS, clinical validation is mixed. Janssen's bermekimab (anti-IL-1α) failed a Phase 2b HS trial due to futility, showing no separation from placebo. While AbbVie's lutikizumab (dual IL-1α/β inhibitor) succeeded in Phase 2, it remains unclear if targeting IL-1β exclusively will yield sufficient efficacy. Additionally, AVTX-009 is a repurposed asset originally developed by Eli Lilly for diabetes and later abandoned, passing through Leap Therapeutics before reaching Avalo. Furthermore, LOTUS uses a highly rigorous primary endpoint: HiSCR75 at Week 16. Most Phase 2 HS trials utilize the lower HiSCR50 bar. Achieving a statistically significant HiSCR75 separation with roughly 83 patients per arm requires a massive effect size, comparable to highly efficacious IL-17 inhibitors, which may be difficult for an unproven IL-1β inhibitor to replicate. Given the notoriously variable placebo response in HS trials, the aggressive endpoint, and the mixed precedent for IL-1 targeted therapies, the intrinsic probability of a positive readout is estimated at 35%.

The trial is in Phase 2, evaluating the efficacy and safety of AVTX-009 for Hidradenitis Suppurativa. The primary endpoint is HiSCR75 at Week 16, a significant and clinically relevant measure. Given the active status and the sponsor's focus, there's a reasonable chance of positive results. However, the small sample size and short duration may limit the outcome's reliability.